What is a potential severe side effect of Dofetilide that requires monitoring?

Dofetilide is an antiarrhythmic medication used primarily to treat atrial fibrillation and atrial flutter. One of the potential severe side effects associated with its use is Torsades de pointes, a life-threatening form of polymorphic ventricular tachycardia that can lead to syncope and sudden cardiac death. Dofetilide prolongs the QT interval on an electrocardiogram, and this can predispose patients to Torsades de pointes, especially if they have other risk factors like electrolyte imbalances or are taking other medications that also prolong the QT interval.

Due to the risk of Torsades de pointes, it is essential for healthcare providers to monitor the ECG and electrolyte levels (particularly potassium and magnesium) in patients receiving Dofetilide. This vigilance helps to catch any significant QT prolongation early and allows for timely intervention if necessary.

Other potential side effects, such as peripheral edema, bradycardia, and palpitations, are not as severe or life-threatening as Torsades de pointes, making the latter a critical focus for monitoring in patients taking Dofetilide. Monitoring the QT interval is a standard practice in managing patients on Dofetilide